Ernest T. Hawk

22.2k total citations · 2 hit papers
170 papers, 9.0k citations indexed

About

Ernest T. Hawk is a scholar working on Oncology, Pharmacology and Cancer Research. According to data from OpenAlex, Ernest T. Hawk has authored 170 papers receiving a total of 9.0k indexed citations (citations by other indexed papers that have themselves been cited), including 58 papers in Oncology, 49 papers in Pharmacology and 37 papers in Cancer Research. Recurrent topics in Ernest T. Hawk's work include Inflammatory mediators and NSAID effects (49 papers), Genetic factors in colorectal cancer (24 papers) and Colorectal Cancer Screening and Detection (24 papers). Ernest T. Hawk is often cited by papers focused on Inflammatory mediators and NSAID effects (49 papers), Genetic factors in colorectal cancer (24 papers) and Colorectal Cancer Screening and Detection (24 papers). Ernest T. Hawk collaborates with scholars based in United States, United Kingdom and Canada. Ernest T. Hawk's co-authors include Monica M. Bertagnolli, Scott M. Lippman, Ann G. Zauber, Ronald A. Lubet, Peter Finn, Scott D. Solomon, Janet Wittes, Jaye L. Viner, William F. Anderson and John J.V. McMurray and has published in prestigious journals such as New England Journal of Medicine, JAMA and Angewandte Chemie International Edition.

In The Last Decade

Ernest T. Hawk

166 papers receiving 8.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention

2005 1.6k citations Ann G. Zauber, Ernest T. Hawk et al. profile →
Statins and cancer prevention

2005 647 citations Ernest T. Hawk, Scott M. Lippman et al. Nature reviews. Cancer profile →

Peers

Countries citing papers authored by Ernest T. Hawk

Since Specialization

Citations

This map shows the geographic impact of Ernest T. Hawk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ernest T. Hawk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ernest T. Hawk more than expected).

Fields of papers citing papers by Ernest T. Hawk

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ernest T. Hawk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ernest T. Hawk. The network helps show where Ernest T. Hawk may publish in the future.

Co-authorship network of co-authors of Ernest T. Hawk

This figure shows the co-authorship network connecting the top 25 collaborators of Ernest T. Hawk. A scholar is included among the top collaborators of Ernest T. Hawk based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ernest T. Hawk. Ernest T. Hawk is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Multi-cancer early detection tests: Attributes for clinical implementation 2025 ·Cancer Biomarkers ·Jon O. Ebbert, Ernest T. Hawk, Christopher V. Chambers, (unknown), Elliot K. Fishman, Joseph Ravenell, Tomasz M. Beer, Seema Rego	0
2	Protection against fibrosis by a bacterial consortium in metabolic dysfunction-associated steatohepatitis and the role of amino acid metabolism 2024 ·Gut Microbes ·Suet‐Ying Kwan, (unknown), Mohamed A. Jamal, Heather L. Stevenson, (unknown), Philip L. Lorenzi, P. Andrew Futreal, Ernest T. Hawk, Joseph B. McCormick, Susan P. Fisher‐Hoch, Robert R. Jenq, Laura Beretta	2
3	Implementation of Universal Hepatitis C Virus Screening in a Tertiary Cancer Center 2024 ·Journal of the National Comprehensive Cancer Network ·Harrys A. Torres, (unknown), (unknown), Jessica Hwang, (unknown), (unknown), Ernest T. Hawk, Bruno Granwehr, (unknown), Anita K. Ying	1
4	Independent of Primary Sclerosing Cholangitis and Cirrhosis, Early Adulthood Obesity Is Associated with Cholangiocarcinoma 2023 ·Cancer Epidemiology Biomarkers & Prevention ·Rikita Hatia, (unknown), Ernest T. Hawk, (unknown), (unknown), Ahmed Shalaby, Ahmed Abdelhakeem, Reham Abdel‐Wahab, Ping Chang, Asif Rashid, Prasun K. Jalal, Christopher I. Amos, Younghun Han, Tannaz Armaghany, Rachna T. Shroff, Donghui Li, Milind Javle, Manal M. Hassan	2
5	Creating and Activating an Implementation Community to Drive HPV Vaccine Uptake in Texas: The Role of an NCI-Designated Cancer Center 2023 ·Vaccines ·(unknown), Michael T. Walsh, (unknown), (unknown), Katherine Oestman, Stephanie Nutt, (unknown), (unknown), Ruth Rechis, Erica M. Bednar, (unknown), Lewis E. Foxhall, (unknown), Sanjay Shete, Ernest T. Hawk	2
6	Gut Microbiome Alterations Associated with Diabetes in Mexican Americans in South Texas 2022 ·mSystems ·Suet‐Ying Kwan, (unknown), Aron Y. Joon, Peng Wei, Lauren E. Petty, Jennifer E. Below, Xiaogang Wu, Jianhua Zhang, Robert R. Jenq, Ernest T. Hawk, (unknown), Susan P. Fisher‐Hoch, Laura Beretta	25
7	MD Anderson's Population Health Approaches to Cancer Prevention. 2018 ·PubMed ·Lewis E. Foxhall, (unknown), Ernest T. Hawk	1
8	Molecular cancer prevention: Current status and future directions 2015 ·CA A Cancer Journal for Clinicians ·Karen Colbert Maresso, Kenneth Y. Tsai, Powel H. Brown, Éva Szabó, Scott M. Lippman, Ernest T. Hawk	67
9	Genetic Polymorphisms in MicroRNA-Related Genes as Predictors of Clinical Outcomes in Colorectal Adenocarcinoma Patients 2012 ·Clinical Cancer Research ·Moubin Lin, Jian Gu, Cathy Eng, Lee M. Ellis, Michelle A.T. Hildebrandt, Jie Lin, Maosheng Huang, George A. Călin, Dingzhi Wang, Raymond N. DuBois, Ernest T. Hawk, Xifeng Wu	56
10	C-reactive Protein and Risk of Colorectal Adenoma According to Celecoxib Treatment 2011 ·Cancer Prevention Research ·Andrew T. Chan, Camelia S. Sima, Ann G. Zauber, Paul M. Ridker, Ernest T. Hawk, Monica M. Bertagnolli	18
11	The Influence of UGT1A6 Variants and Aspirin Use in a Randomized Trial of Celecoxib for Prevention of Colorectal Adenoma 2011 ·Cancer Prevention Research ·Andrew T. Chan, Meier Hsu, Ann G. Zauber, Ernest T. Hawk, Monica M. Bertagnolli	13
12	Genome-Wide Catalogue of Chromosomal Aberrations in Barrett's Esophagus and Esophageal Adenocarcinoma: A High-Density Single Nucleotide Polymorphism Array Analysis 2010 ·Cancer Prevention Research ·Jian Gu, Jaffer A. Ajani, Ernest T. Hawk, Yuanqing Ye, Jeffrey H. Lee, Manoop S. Bhutani, Wayne L. Hofstetter, Stephen G. Swisher, Kenneth K. Wang, Xifeng Wu	67
13	Cancer Prevention: From 1727 to Milestones of the Past 100 Years 2009 ·Cancer Research ·Scott M. Lippman, Ernest T. Hawk	97
14	Aberrant Crypt Foci in the Adenoma Prevention with Celecoxib Trial 2008 ·Cancer Prevention Research ·Nancy L. Cho, Mark Redston, Ann G. Zauber, Adelaide M. Carothers, Jason L. Hornick, Andrew S. Wilton, Stephen J. Sontag, Norman S. Nishioka, Francis M. Giardiello, John R. Saltzman, (unknown), Craig Eagle, Ernest T. Hawk, Monica M. Bertagnolli	46
15	Difluoromethylornithine Plus Sulindac for the Prevention of Sporadic Colorectal Adenomas: A Randomized Placebo-Controlled, Double-Blind Trial 2008 ·Cancer Prevention Research ·Frank L. Meyskens, Christine E. McLaren, Daniel Pelot, Sharon Fujikawa-Brooks, Philip M. Carpenter, Ernest T. Hawk, Gary J. Kelloff, Michael J. Lawson, Jayashri Kidao, John A. McCracken, Gregory Albers, Dennis J. Ahnen, D. Kim Turgeon, Steven Goldschmid, Peter Lance, Curt H. Hagedorn, Daniel L. Gillen, Eugene W. Gerner	392
16	Cancer Chemoprevention 2004 ·Humana Press eBooks ·Gary J. Kelloff, Ernest T. Hawk, Caroline C. Sigman	14
17	Promising cancer chemopreventive agents 2004 ·Humana Press eBooks ·Gary J. Kelloff, Ernest T. Hawk, Caroline C. Sigman	9
18	Testing guidelines for hereditary non-polyposis colorectal cancer 2004 ·Nature reviews. Cancer ·Asad Umar, John I. Risinger, Ernest T. Hawk, J. Carl Barrett	131
19	Oltipraz Concentrations in Plasma, Buccal Mucosa Cells,and Lipids 2001 ·Cancer Epidemiology and Prevention Biomarkers ·Nikolay V. Dimitrov, (unknown), (unknown), (unknown), Maurice R. Bennink, Joseph C. Gardiner, James A. Crowell, Ernest T. Hawk, (unknown), James L. Bennett	1
20	Progress in Cancer Chemoprevention: Development of Diet-Derived Chemopreventive Agents 2000 ·Journal of Nutrition ·Gary J. Kelloff, James A. Crowell, Vernon E. Steele, Ronald A. Lubet, (unknown), Charles W. Boone, Levy Kopelovich, Ernest T. Hawk, Ronald Lieberman, Julia Lawrence, Imran Ali, Jaye L. Viner, Caroline C. Sigman	382

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact